MERCK KGaA
- Pharmaceutical Sales 2010
-
Worldwide: 6.225 billion Euro
In germany: 554 million Euro
- Product Range
- Cancer (colon, head & neck), neurodegenerative diseases (multiple sclerosis), fertilisation, endocrinological diseases (growth hormone disorders), HIV-associated wasting, hyperphenylalaninemia (orphan drug for treatment of rare disease), diabetes type 2, cardiovascular diseases, thyroid disorders, as well as several indications in the field of self-medication
- Key Research Areas
-
Oncology, neurodegenerative diseases, rheumatological indications (e.g. lupus erythematodes or arthrosis). Besides Merck is researching in fertile diseases;
Mercks R&D pipeline consisted of 6 Phase I projects, 7 Phase II projects and 9 Phase III projects in 2010. - R&D Expenditure 2010
-
Worldwide: 1.192 billion EURO
- Employees in the Pharmaceuticals Division 2010
-
Worldwide: 18,742
Germany: 2,350
(All data based on corporate information, as of: 12/2010)
Unless indicated otherwise, data and keywords refer to the company's human therapeutics sector in Germany and to that of its international Group worldwide.
Unless indicated otherwise, data and keywords refer to the company's human therapeutics sector in Germany and to that of its international Group worldwide.
Suggest page
Print page
Bookmark page